Improvement in profitability of the metabolome analysis business
First written in FY2016-Q4. 16 of 36 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026WorsenedAnnual report
「As a result, revenue was ¥1,421.944 million, down 2.3% from the previous consolidated fiscal year, operating profit was ¥209.911 million, down 15.9%, ordinary profit was ¥206.691 million, down 14.2%, and profit attributable to owners of the parent was ¥200.358 million, down 21.9%.」
Following the transition to a single-segment structure, revenue, operating profit, ordinary profit and net profit for the period were all below the same period of the previous year on a company-wide basis. - FY2025-H1WorsenedAnnual report
「As a result, revenue for the segment as a whole was ¥527.801 million, up 2.1% year on year. In addition, concentrated investment in research and development for the “biomanufacturing” productivity improvement support service increased segment expenses, resulting in segment profit after allocation of corporate expenses of ¥76.052 million, down 19.6%.」
The advanced research and development support business generated higher revenue, while concentrated investment in the “biomanufacturing” productivity improvement support service increased segment expenses, causing segment profit to decline 19.6% year on year. - FY2024WorsenedAnnual report
「As a result, revenue was ¥1,186.852 million, down 5.2% year on year. Segment profit after allocation of corporate expenses was ¥310.700 million, down 12.1%.」
The advanced research and development support business generated lower revenue and lower profit, with segment profit declining from ¥353.609 million to ¥310.700 million. - FY2024-Q3WorsenedAnnual report
「As a result, revenue was ¥963.363 million, down 7.9% year on year, and segment profit after allocation of corporate expenses was ¥299.387 million, down 19.8%.」
The advanced research and development support business generated lower revenue and lower profit, with revenue down 7.9% year on year and segment profit down 19.8%. - FY2024-Q2WorsenedAnnual report
「As a result, revenue was ¥516.990 million, down 12.0% year on year, and segment profit after allocation of corporate expenses was ¥94.565 million, down 38.5%.」
The advanced research and development support business generated lower revenue and lower profit, with revenue down 12.0% year on year and segment profit down 38.5%. - FY2024-Q1WorsenedAnnual report
「As a result, revenue was ¥221.257 million, down 13.5% year on year. In addition to lower revenue, higher cost of sales associated with the introduction of cutting-edge equipment and increased sales of partner services affected segment profit after allocation of corporate expenses, which was ¥3.900 million, down 89.9%.」
The advanced research and development support business generated lower revenue, while the increase in cost of sales associated with the introduction of cutting-edge equipment and increased sales of partner services also contributed to an 89.9% year-on-year decline in segment profit. - FY2023AdvancedAnnual report
「Segment profit after allocation of corporate expenses was ¥353.609 million, up 6.5% year on year.」
Segment profit in the advanced research and development support business increased from ¥331.992 million to ¥353.609 million, and earning power continued to improve. - FY2023-Q3AdvancedAnnual report
「As a result, revenue was ¥1,045.761 million, up 3.8% year on year, and segment profit after allocation of corporate expenses was ¥373.253 million, up 4.1%.」
The advanced research and development support business generated higher revenue and higher profit, with segment profit of ¥373.253 million, up 4.1% year on year. - FY2023-Q2AdvancedAnnual report
「As a result, revenue was ¥587.789 million, up 10.6% year on year, and segment profit after allocation of corporate expenses was ¥153.646 million, up 15.4%.」
The advanced research and development support business generated higher revenue and higher profit, indicating specific improvements in revenue and segment profit. - FY2023-Q1AdvancedAnnual report
「As a result, revenue was ¥255.674 million, up 47.3% year on year, and segment profit after allocation of corporate expenses was ¥38.684 million, compared with a segment loss of ¥19.596 million in the same period of the previous year.」
The advanced research and development support business generated 47.3% higher revenue year on year, and moved from a segment loss to a profit of ¥38.684 million. - FY2022AdvancedAnnual report
「As a result, revenue was ¥1,220.425 million, up 9.0% year on year. Segment profit also increased substantially, reaching ¥331.992 million, up 134.9%, due in addition to higher revenue to substantial reductions in selling, general and administrative expenses, including those resulting from the closure of a European subsidiary.」
The advanced research and development support business generated higher revenue, while segment profit was ¥331.992 million, up 134.9% year on year. - FY2022-Q3AdvancedAnnual report
「As a result, revenue was ¥1,007.483 million, up 9.1% year on year, and segment profit was ¥358.589 million, up 101.6%.」
The advanced research and development support business generated higher revenue and higher profit, with revenue up 9.1% year on year and segment profit up 101.6%. - FY2022-Q2AdvancedAnnual report
「As a result, revenue was ¥531.565 million, down 0.7% year on year, and segment profit after allocation of corporate expenses was ¥133.117 million, up 125.7%.」
The advanced research and development support business generated lower revenue, while segment profit was ¥133.117 million, up 125.7% year on year. - FY2022-Q1WorsenedAnnual report
「As a result, revenue was ¥173.522 million, down 29.1% year on year, and the segment loss after allocation of corporate expenses was ¥19.596 million, compared with a segment loss of ¥5.442 million in the same period of the previous year.」
The advanced research and development support business generated 29.1% lower revenue year on year, while the segment loss widened from ¥5.442 million to ¥19.596 million. - FY2021WorsenedAnnual report
「Segment profit declined because cost of sales increased due mainly to higher depreciation expenses associated with expanded facilities and higher outsourcing expenses associated with increased sales of new services, reaching ¥423.485 million, down 7.4% year on year.」
The metabolomics business generated revenue of ¥1,119.593 million, up 0.5% year on year, while segment profit declined 7.4% year on year. - FY2021-Q3WorsenedAnnual report
「As a result, revenue was ¥923.697 million, down 6.7% year on year, and segment profit was ¥391.422 million, down 21.0%.」
The metabolomics business generated lower revenue and lower profit, with revenue down 6.7% year on year and segment profit down 21.0%. - FY2021-Q2AdvancedAnnual report
「As a result, revenue was ¥535.305 million, up 18.1% year on year, and segment profit was ¥181.437 million, up 42.2%.」
The metabolomics business generated higher revenue and higher profit, indicating specific improvements in revenue and segment profit. - FY2021-Q1AdvancedAnnual report
「As a result, revenue was ¥244.837 million, up 23.8% year on year, and segment profit was ¥60.608 million, up 91.3%.」
Revenue from the metabolomics business increased 23.8% year on year, while segment profit increased 91.3%. - FY2020AdvancedAnnual report
「As a result, revenue was ¥1,114.180 million and segment profit was ¥457.128 million.」
The metabolomics business recorded revenue of ¥1,114.180 million and segment profit of ¥457.128 million. Although direct comparison is constrained because the previous fiscal year covered a 15-month period, the figures indicate higher revenue across all fields and the generation of profit. - FY2020-Q3AdvancedAnnual report
「As a result, sales were ¥990.327 million, and segment profit was ¥495.320 million, partly because the company worked to improve operating efficiency, including the utilization rate.」
The metabolomics business recorded revenue of ¥990.327 million and segment profit of ¥495.320 million. It was explained that revenue increased across all fields compared with the same period of the previous year. - FY2020-Q2RestatedAnnual report
「As a result, sales were ¥453.226 million, and segment profit was ¥127.554 million, partly because the company worked to improve operating efficiency, including the utilization rate.」
The metabolomics business generated revenue of ¥453.226 million and segment profit of ¥127.554 million. Because the corresponding period of the previous consolidated fiscal year differed, the direction of improvement or deterioration in earnings is not presented on a comparable basis. - FY2020-Q1RestatedAnnual report
「As a result, revenue was ¥197.835 million and segment profit was ¥31.682 million.」
The metabolomics business generated revenue of ¥197.835 million and segment profit of ¥31.682 million. Because the fiscal year-end change meant that no comparison with the same quarter of the previous year was made, the direction of improvement or deterioration is not presented on a comparable basis. - FY2019WorsenedAnnual report
「Revenue from the metabolomics business was ¥988.986 million, and segment profit was ¥232.903 million.」
Segment profit declined from ¥445.146 million in the previous consolidated fiscal year to ¥232.903 million. Although the 15-month fiscal period should be taken into account, the full-year figures indicate a deterioration in earning power. - FY2019-Q3RestatedAnnual report
「As a result, revenue was ¥834.095 million and segment profit was ¥238.748 million.」
The metabolomics business recorded revenue of ¥834.095 million and segment profit of ¥238.748 million. Because no comparison with the same quarter of the previous year was made during the 15-month irregular fiscal period, the direction of change in earnings is not presented on a comparable basis. - FY2019-Q2WorsenedAnnual report
「However, during the cumulative consolidated third quarter, revenue was ¥438.646 million, down 15.5% year on year, and segment profit was ¥18.997 million, down 87.7%, due mainly to the absence of large orders such as those received in the same period of the previous year and sluggish order intake in the first half.」
The metabolomics business generated lower revenue, and segment profit also declined substantially, falling 87.7% year on year. - FY2019-Q1WorsenedAnnual report
「However, during the cumulative consolidated second quarter, revenue was ¥276.414 million, down 10.1% year on year, and segment profit was ¥5.947 million, down 91.1%, due mainly to the absence of large orders such as those received in the same period of the previous year and sluggish customer budget execution.」
The metabolome analysis business generated lower revenue, and segment profit also declined substantially, falling 91.1% year on year. - FY2018-Q4AdvancedAnnual report
「As a result, revenue was ¥150.858 million, up 28.4% year on year, and segment profit was ¥28.825 million, up 196.6%.」
The metabolome analysis business generated higher revenue, and segment profit also increased substantially, rising 196.6% year on year. - FY2018-Q2WorsenedAnnual report
「As a result, revenue was ¥519.249 million, up 1.9% year on year, and segment profit was ¥154.401 million, down 25.7%.」
The metabolome analysis business generated higher revenue, while segment profit declined 25.7% year on year. - FY2018-Q1WorsenedAnnual report
「As a result, revenue was ¥307.549 million, up 12.6% year on year, and segment profit was ¥66.636 million, down 20.0%.」
The metabolome analysis business generated higher revenue, while segment profit declined 20.0% year on year. - FY2017-Q4AdvancedAnnual report
「As a result, revenue was ¥117.536 million, up 26.0% year on year, and segment profit was ¥9.717 million, up 416.2%.」
Revenue from the metabolome analysis business increased 26.0% year on year, while segment profit increased 416.2%. - FY2017AdvancedAnnual report
「As a result, sales were ¥913.458 million, up 29.8% year on year, and segment profit was ¥501.010 million, up 66.8%.」
Full-year sales and segment profit in the metabolome analysis business increased substantially. - FY2017-Q2AdvancedAnnual report
「As a result, sales were ¥509.361 million, up 32.3% year on year, and segment profit was ¥207.783 million, up 151.2%.」
Sales in the metabolome analysis business increased 32.3% year on year, and segment profit increased 151.2%. - FY2017-Q1AdvancedAnnual report
「As a result, revenue was ¥273.190 million, up 11.4% year on year, and segment profit was ¥83.293 million, up 95.3%.」
The company reported that sales in the metabolome analysis business increased 11.4% year on year and segment profit increased 95.3%. - FY2016-Q4First statedAnnual report
「As a result, sales were ¥93.293 million, up 20.2% year on year, and segment profit was ¥1.882 million, compared with a segment loss of ¥24.951 million in the same period of the previous year.」
The company reported a 20.2% year-on-year increase in sales and a swing from a segment loss to segment profit of ¥1.882 million.